185 related articles for article (PubMed ID: 30909702)
1. Treatment of antibody immunodeficiency.
Litzman J
Vnitr Lek; 2019; 65(2):126-130. PubMed ID: 30909702
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.
Jolles S; Bernatowska E; de Gracia J; Borte M; Cristea V; Peter HH; Belohradsky BH; Wahn V; Neufang-Hüber J; Zenker O; Grimbacher B
Clin Immunol; 2011 Oct; 141(1):90-102. PubMed ID: 21705277
[TBL] [Abstract][Full Text] [Related]
3. Immune globulin (human) 10 % liquid: a review of its use in primary immunodeficiency disorders.
McCormack PL
BioDrugs; 2013 Aug; 27(4):393-400. PubMed ID: 23703447
[TBL] [Abstract][Full Text] [Related]
4. Reversible Hypogammaglobulinemia in 2 Pediatric Patients With Primary Immunodeficiency.
Pasic S
J Investig Allergol Clin Immunol; 2017; 27(5):320-321. PubMed ID: 29057740
[No Abstract] [Full Text] [Related]
5. Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies.
Gustafson R; Gardulf A; Hansen S; Leibl H; Engl W; Lindén M; Müller A; Hammarström L
Clin Exp Immunol; 2008 May; 152(2):274-9. PubMed ID: 18341618
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients.
Compagno N; Cinetto F; Semenzato G; Agostini C
Haematologica; 2014 Jun; 99(6):1101-6. PubMed ID: 24682509
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs.
Gardulf A; Andersen V; Björkander J; Ericson D; Frøland SS; Gustafson R; Hammarström L; Jacobsen MB; Jonsson E; Möller G
Lancet; 1995 Feb; 345(8946):365-9. PubMed ID: 7845120
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous Immunoglobulin Therapy for Hypogammaglobulinemia Secondary to Malignancy or Related Drug Therapy.
Windegger TM; Lambooy CA; Hollis L; Morwood K; Weston H; Fung YL
Transfus Med Rev; 2017 Jan; 31(1):45-50. PubMed ID: 27450021
[TBL] [Abstract][Full Text] [Related]
9. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.
Chapel HM; Spickett GP; Ericson D; Engl W; Eibl MM; Bjorkander J
J Clin Immunol; 2000 Mar; 20(2):94-100. PubMed ID: 10821460
[TBL] [Abstract][Full Text] [Related]
10. [Subcutaneous immunoglobulin substitution and therapy].
Gulácsy V; Maródi L
Orv Hetil; 2011 Jan; 152(2):64-7. PubMed ID: 21177233
[TBL] [Abstract][Full Text] [Related]
11. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency.
Aghamohammadi A; Farhoudi A; Nikzad M; Moin M; Pourpak Z; Rezaei N; Gharagozlou M; Movahedi M; Atarod L; Afshar AA; Bazargan N; Hosseinpoor AR
Ann Allergy Asthma Immunol; 2004 Jan; 92(1):60-4. PubMed ID: 14756466
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency.
Patel V; Cowan J
Expert Rev Clin Immunol; 2020 Jul; 16(7):711-716. PubMed ID: 32588670
[TBL] [Abstract][Full Text] [Related]
13. [Prevention of infections in primary and secondary antibody deficiency].
Mikołuć B; Pietrucha B; Motkowski R; Wolska-Kuśnierz B; Heropolitańska-Pliszka E; Bernatowska E
Przegl Epidemiol; 2009; 63(1):55-60. PubMed ID: 19522227
[TBL] [Abstract][Full Text] [Related]
14. Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia.
Spadaro G; Pecoraro A; De Renzo A; Della Pepa R; Genovese A
Clin Immunol; 2016 May; 166-167():103-4. PubMed ID: 27063866
[TBL] [Abstract][Full Text] [Related]
15. Advantage of the subcutaneous immunoglobulin replacement therapy in primary immunodeficient patients with or without secondary protein loss.
Gür-Çetinkaya P; Çağdaş-Ayvaz DN; Öksüz AB; Ertoy A; Hayran U; Özkan F; Erol M; Tezcan İ
Turk J Pediatr; 2018; 60(3):270-276. PubMed ID: 30511539
[TBL] [Abstract][Full Text] [Related]
16. Clinical use of immune serum globulin as replacement therapy in patients with primary immunodeficiency syndromes.
Schwartz SA
Clin Rev Allergy; 1992; 10(1-2):1-12. PubMed ID: 1606517
[TBL] [Abstract][Full Text] [Related]
17. Increase of serum immunoglobulin level into the normal range in primary hypogammaglobulinaemia by dosage individualization of intravenous immunoglobulin.
Leen CL; Yap PL; McClelland DB
Vox Sang; 1986; 51(4):278-86. PubMed ID: 3798863
[TBL] [Abstract][Full Text] [Related]
18. Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels.
Thépot S; Malphettes M; Gardeur A; Galicier L; Asli B; Karlin L; Gérard L; Laumont R; Doize ML; Arnulf B; Fieschi C; Bengoufa D; Oksenhendler E
J Clin Immunol; 2010 Jul; 30(4):602-6. PubMed ID: 20393788
[TBL] [Abstract][Full Text] [Related]
19. Antibody replacement therapy in primary antibody deficiencies and iatrogenic hypogammaglobulinemia.
Hoffman TW; van Kessel DA; van Velzen-Blad H; Grutters JC; Rijkers GT
Expert Rev Clin Immunol; 2015; 11(8):921-33. PubMed ID: 26181342
[TBL] [Abstract][Full Text] [Related]
20. Measles antibody trough levels after treatment with immunoglobulin products and predicted levels assuming lower measles antibody specifications.
Vandeberg P; Cruz MC; Griffin R
Transfusion; 2018 Dec; 58 Suppl 3():3072-3077. PubMed ID: 30430616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
